ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) is a pharmaceutical company that develops and commercializes medicines for central nervous system disorders. Revenue is generated through product sales of its approved prescription drugs. The 10-K filed 2026-02-26 covers fiscal year ended December 31, 2025, confirming ACADIA operates as a commercial-stage biopharmaceutical company. The filing excerpts provided do not contain sufficient detail to report specific revenue figures, segment breakdowns, customer concentration, competitor names, geographic mix, or capital structure with the specificity required for this description. What the filing confirms is that ACADIA is a well-known seasoned issuer listed on a U.S. exchange under the ticker ACAD, incorporated in a U.S. state, with annual reporting obligations under Section 13 or 15(d) of the Securities Exchange Act. Additional financial and operational detail would require access to the full text of the MD&A and financial statements sections of this filing.

Revenue model

Prescription drug product sales. Specific products, pricing, and revenue figures are not supported by the provided filing excerpts.

Products and services

Central nervous system disorder treatments. Specific approved products are not named in the provided filing excerpts.

Customers and end markets

Central nervous system therapeutics end market. Specific customer types and concentration data are not supported by the provided filing excerpts.

Value-chain role

Commercial-stage drug developer and marketer.

Geographic exposure

U.S.-listed company. Geographic revenue mix not supported by the provided filing excerpts.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: AMICUS THERAPEUTICS, INC. Arrowhead Pharmaceuticals Inc Beam Therapeutics Inc BioCryst Pharmaceuticals Inc Denali Therapeutics Inc Insmed Inc Relay Therapeutics Inc Ultragenyx Pharmaceutical Inc Vir Biotechnology Inc